SEC Form 4 · accession 0001104659-18-022602
Axsome Therapeutics, Inc. · AXSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Coleman
Director
Period of report
Mar 12, 2018
Accepted (ET)
Apr 5, 2018 · 10:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001579428
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.85 | Mar 12, 2018 | A | 27,297 | A | Mar 12, 2018 | Mar 11, 2028 | Common Stock | 27,297 | 27,297 | D |
Explanation of responses
- F1Represents 27,297 options elected to be received in lieu of cash compensation earned in 2017. All of such options are immediately exercisable.